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ABSTRACT
The interactions of N4-octadecyl-1-b-D-arabinofuranosylcy-
tosine (NOAC), a lipophilic derivative of 1-b-D-arabinofurano-
sylcytosine (ara-C), were studied in vitro with human blood
components. Binding of NOAC incorporated into liposomes to
erythrocytes (Ec) was saturated at 63 nmol/109 Ec and binding
analysis resulted in a weak affinity of 3 3 103 liters/mol and 4 3
107 binding sites per Ec. The Ec partition coefficient DEc was
approximately 4, which demonstrates the high accumulation of
NOAC in Ec membranes. The calculated fraction fb of drug
bound to plasma proteins was 30%. Analysis of serum protein
binding of NOAC was done by density gradient ultracentrifuga-
tion and agarose gel electrophoresis. Liposomal NOAC was
distributed to low-density lipoproteins (LDL) at 36%, to high-
density lipoproteins at 21%, to albumin and other proteins at
12% and to very-low-density lipoproteins at 5%. Comparable
results were obtained for the analog N4-hexadecyl-1-b-D-ar-
abinofuranosylcytosine and when the drugs were dissolved in
dimethyl sulfoxide. The biodistribution of liposomal NOAC in
ICR mice after intravenous application revealed a biphasic
blood concentration versus time curve with a distribution half-
life t1/2a of 23 min and an elimination half-life t1/2b of 7 h. The
drug was distributed mainly into the liver with an organ load of
69% and with an elimination half-life of 8 h. The strong affinity
of NOAC to LDL might be exploited for the enhanced uptake of
the drug in tumor cells expressing high numbers of LDL recep-
tor molecules.
1-b-D-Arabinofuranosylcytosine is an effective chemother-
apeutic agent for the treatment of acute myelogenous leuke-
mia (Gahrton, 1983; Keating et al., 1982; Plunkett and Gan-
dhi, 1993). However, its usefulness is impaired by its rapid
deamination to the biologically inactive metabolite ara-U (Ho
and Frei, 1971). To increase the cytotoxic activity of ara-C
numerous N4-derivatives were synthesized to protect the
drug from deamination and to alter its pharmacokinetic
properties (Kanai and Ichino, 1974; Rosowsky et al., 1982;
Wempen et al., 1968). Whereas short-chain modifications of
ara-C at the N4-amino group generally resulted in a weak
enhancement of cytotoxicity (Aoshima et al., 1976), lipophilic
derivatives with long-chain fatty acids had a strong antitu-
mor activity in murine tumor models (Kataoka and Sakurai,
1980; Tsuruo et al., 1980). In a previous study, we reported
that N4-acyl derivatives of ara-C, incorporated into the mem-
branes of small unilamellar liposomes, were active against
murine L1210 leukemia and B16 melanoma at lower concen-
trations than unmodified ara-C (Rubas et al., 1986). How-
ever, the protection against enzymatic deamination to ara-U
was only partially achieved with the N4-acyl derivatives.
Therefore we synthesized the N4-alkyl-ara-C derivatives
NHAC and NOAC shown in figure 1 (Schwendener et al.,
1995a; Schwendener and Schott, 1992). These derivatives
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were found to be extremely resistant toward deamination in
plasma as well as in the liver (Schwendener et al., 1995b).
Because of the very low solubility in aqueous media NHAC
and NOAC were incorporated into the lipid membranes of
small unilamellar liposomes to allow their parenteral appli-
cation. Liposomal preparations of NHAC and NOAC exerted
significantly higher cytotoxic activities in the L1210 leuke-
mia model than ara-C. In contrast to the parent drug and to
some other lipophilic ara-C derivatives, NHAC and NOAC
were found to exert excellent antitumor effects after oral
therapy (Schwendener et al., 1996; Schwendener and Schott,
1996). We conclude from these and the following findings
that the mechanisms of action of the N4-alkyl-ara-C deriva-
tives are different from ara-C. Their cellular uptake is nucle-
oside-transporter independent and only 2 to 5% were phos-
phorylated to ara-C triphosphate in HL-60, K-562 and U-937
cells (Horber et al., 1995b, c). The cytotoxicity of NHAC was
found to be less S-phase specific than ara-C, and induction of
apoptosis occurred only at very high drug concentrations
(Horber et al., 1995d). Presently, we concentrate our studies
on NOAC because this derivative has the highest antitumor
activity of all N4-alkyl analogs (Schwendener et al., 1995a). A
phase I/II study of liposomal NOAC is currently underway at
the University Hospital Zurich.
It is known that single-chain acyl compounds like fatty
acids are not tightly anchored within the lipid bilayer of
liposomes and that they are readily transferred to plasma
proteins and Ec membranes (Kamp et al., 1993; Kleinfeld and
Storch, 1993; Richieri et al., 1993). We assumed that the
N4-alkyl-ara-C derivatives, which have no amphiphilic prop-
erties and are not charged at physiological pH, move through
lipid membranes of the liposomes and are transferred to
blood components at rates that are comparable with long-
chain fatty acids.
Therefore, in this report we investigated the interactions of
NOAC with human blood in vitro and compared them with
the properties of NHAC. Ec binding was measured and pro-
tein binding was calculated with the Ec partition coefficient
DEc. In addition, we studied the distribution of the drugs
between the serum lipoproteins which were separated by
ultracentrifugation on a KBr density gradient and analyzed
on agarose gels. In the second part of this contribution we
determined the blood and organ distribution in vivo of lipo-
somal NOAC in ICR mice and calculated the pharmacoki-
netic parameters.
Methods
Chemicals. NHAC and NOAC were synthesized as described
previously (fig. 1; Schwendener et al., 1995a; Schwendener and
Schott, 1992). SPC was obtained from L. Meyer, Hamburg, Germany.
Cholesterol (Fluka AG, Buchs, Switzerland) was recrystallized from
methanol. DL-a-Tocopherol and all analytical grade buffer salts and
other chemicals used were from Merck, Darmstadt, Germany or
Fluka, Buchs, Switzerland. NHAC and NOAC were tritium labeled
(0.189 Gbq/mmol [5-3H]NHAC and 0.370 Gbq/mmol [5-3H]NOAC) by
Amersham Int., Amersham, UK. Soluene 350 and Ultima Gold scin-
tillation cocktail were from Packard Instruments, Groningen, The
Netherlands.
Preparation of liposomes. Small unilamellar liposomes were
prepared by sequential filter extrusion of multilamellar liposomal
preparations through Nuclepore membranes (Sterico, Dietikon,
Switzerland) of 0.4 mm, 0.2 mm and 0.1 mm pore diameter with a
Lipex extruder (Lipex Biomembranes Inc., Vancouver, Canada; Hope
et al., 1985). For experiments with human blood or intravenous
injection into mice, liposomes were either prepared in PB (67 mM,
pH 7.4) or in saline, containing 0.01% EDTA (saline/EDTA) for the
incubations with serum. Liposome size and homogeneity were deter-
mined by laser light scattering (Submicron Particle Sizer Model 370,
Nicomp, Santa Barbara, CA). The basic lipid composition of the
liposomes used for in vitro incubations with blood and serum was 40
mg/ml SPC, 4 mg/ml cholesterol, 0.2 mg/ml DL-a-tocopherol and 2.5
mg/ml of the drugs NOAC or NHAC, whereas the liposomes used for
the pharmacokinetic experiments were composed of 80 mg/ml SPC, 8
mg/ml cholesterol, 0.4 mg/ml DL-a-tocopherol and 11 mg/ml NOAC.
All preparations were trace labeled with [5-3H]NOAC or
[5-3H]NHAC, respectively, sterile filtrated (0.2 mm, Schleicher &
Schuell, Dassel, Germany), stored at 4°C and used within 3 days
after preparation. For control experiments stock solutions of NHAC
and NOAC (2.5 mg/ml, corresponding to their highest stable solubil-
ity) in DMSO were prepared.
In vitro distribution of NOAC and NHAC in human blood.
Fresh venous blood was collected in EDTA tubes (Vacutainer, Becton
Dickinson, Meylon Cedex, France) from a healthy donor after an
overnight fast. For the incubation experiments, 1.5 ml blood contain-
ing 6 6 1 3 109 Ec (hematocrit, 0.3–0.4) were spiked either with the
drugs in liposomes or in DMSO to yield final drug concentrations of
60 to 1100 mM (liposomes) or 100 and 200 mM (DMSO) in a total
volume of 2 ml. After incubation on a blood sample shaker (Speci-
mix, Bioblock, Frenkendorf, Switzerland) for 4 h at 37°C the blood
samples were centrifuged (10 min, 650 3 g, 20°C) and plasma was
removed. The blood cells were not separated further, because as
Fig. 1. Chemical structures of ara-C, NOAC and NHAC.
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shown before with NHAC, binding to leukocytes was negligible (ap-
proximately 2%; Horber et al., 1995a). Thus, the whole-blood cell
fraction was referred to as Ec. The Ec samples were washed three
times with PB, centrifuged (10 min, 650 3 g, 20°C) and then solu-
bilized, and the [5-3H]NOAC or [5-3H]NHAC activity was detected by
scintillation counting as described previously (Horber et al., 1995a).
All experiments were carried out in triplicate. To exclude the possi-
bility of precipitation of NOAC dissolved in DMSO in these incuba-
tions, the following control experiments in diluted serum were per-
formed. The 3H-labeled drug dissolved in 50 ml DMSO (0.28 mM final
concentration) was incubated in 450 ml serum diluted with 500 ml
saline/EDTA for 4 h at 37°C. The serum was centrifuged (650 3 g, 10
min) and the [5-3H]NOAC concentration was determined in the
supernatants. Corresponding controls were made by use of saline/
EDTA instead of serum.
Analysis of binding parameters. To fit the concentration-de-






with Bmax, maximal binding capacity, and Kd, concentration of the
ligand to determine half-maximal binding. The binding parameters
of the two drugs to Ec were calculated from linearized curves of the





with [AEc], drug bound to Ec in millimolar (corresponding to 6.022 3
1020 Ec per liter) and [Ectot], total concentration of Ec in millimolar.
The Ec partition coefficient DEc was calculated according to equation
3:
DEc 5
~Ablood 2 Aplasma!~1 2 H!
HAplasma
(3)
with Ablood, the absolute amount of drug in whole blood (nanomoles);
Aplasma, drug in the plasma fraction (nanomoles) and H, hematocrit
(Derendorf and Garrett, 1983). The plasma protein-binding fraction
fb was determined from DEc as described in equation 4:
fb 5 1 2
Ablood 2 cplasmaVblood~1 2 H!
DEccplasmaVblood~1 2 H!
S1H 2 1D (4)
with cplasma, concentration in the plasma fraction of the probe, and
Vblood, the volume of whole blood.
In vitro distribution of NOAC and NHAC in human serum.
Fresh serum with normal cholesterol and lipoprotein levels was
obtained from a healthy donor after overnight fasting. The blood was
allowed to coagulate for 2 h and then centrifuged (10 min, 650 3 g,
20°C). The drugs (0.1 ml; final concentration, 200 mM) were added
either as liposomal preparation or dissolved in DMSO to 0.9 ml
serum corresponding to the serum contained in 1.5 ml whole blood.
After incubation for 4 h at 37°C on a blood sample shaker the
separation of the plasma proteins was performed by gradient ultra-
centrifugation according to Chapman et al. (1981) and Redgrave et
al. (1975) with small modifications. A density gradient was formed in
ultracentrifuge tubes (Polyallomer, 5 ml, Beckman, Geneva, Swit-
zerland) by adding 0.325 g KBr to 1 ml of the serum supernatants
(d20
20 1.21), which were overlaid sequentially with solutions of 1 ml
KBr in saline of the decreasing densities d20
20 1.064, 1.020 and
1.007. Finally, 1 ml of distilled water was added on top. The probes
containing the drugs in liposomes or in DMSO and the appropriate
controls replacing the serum with saline/EDTA and serum alone (fig.
3) were placed in a SW 50.1 rotor (Beckman, Geneva, Switzerland)
and centrifuged for 22 h at 300,000 3 g and 15°C in an ultracentri-
fuge (Centrikon T-1065, Kontron Instruments, Zu¨rich, Switzerland).
After careful removal of the tubes from the rotor a fine glass capillary
was gently immersed to the bottom of each tube and 50 fractions of
0.17 ml were collected with a fraction collector (Superrac LKB,
Uppsala, Sweden). Protein absorption was monitored continuously
with a flow detector (Uvicord SII, LKB) at 279 nm. Drug concentra-
tion per fraction and initial concentration of the probes were ana-
lyzed by scintillation counting. The densities of the KBr solutions
and of the individual fractions after centrifugation were determined
with a densitometer (DMA 38, Anton Paar KG, Graz, Austria). All
incubations were carried out in triplicate. The separation of the
lipoproteins was controlled by electrophoresis on 1% agarose gels by
a modified method described by Nobel (1968). From each centrifuged
serum fraction an aliquot prestained with Sudan black B was applied
to the gels. To provide further evidence of the transfer of liposomal
NOAC to the lipoproteins, selected HDL- and LDL-rich fractions
from the KBr gradient separation (cf. fig. 3) were run on a gel (cf.
inset, fig. 4), and the bands corresponding to HDL or LDL were cut
and analyzed for [5-3H]NOAC activity (cf. curves in fig. 4).
NOAC pharmacokinetics and organ distribution in mice.
Female mice (ICR, 27–38 g) were injected intravenously in the tail
vein with 2.3 mg (4.6 mmol) liposomal NOAC in a volume of 200 ml.
After periods ranging from 4 min to 24 h groups of three mice were
sacrificed and blood, liver, spleen, kidneys, lung and brain were
collected. To determine the concentration of NOAC in blood and the
organs the samples were solubilized and further treated as described
previously (Horber et al., 1995a). Drug concentrations in organs were
corrected for the remaining blood (Allen, 1989). All values for blood
and organ distribution (figs. 5 and 6) were standardized with the
body weight of a mouse of 20 g and given as percent of disintegra-
tions per min injected per ml blood or as percent of disintegrations
per min injected per total organ.
Pharmacokinetic analysis. The blood concentration versus time
curve (fig. 5A) was approximated by the residual method which led to
equation 5 of a two-compartment open model for intravenous drug
application. The calculated parameters A, B, a and b of equation 5
were used to fit the curve:
y 5 Ae2at 1 Be2bt (5)
where (A 1 B), peak drug concentration in blood at time t 5 0 min.
The distribution t1/2a and elimination t1/2b half-lives were calculated
from the slopes a and b. The apparent volume of distribution Vd(area),
the apparent volume of the central Vc and peripheral Vp compart-
ments, the systemic clearance Cltotal were calculated by equations
described elsewhere (Greenblatt and Koch-Weser, 1975). The area
under the curve for time zero to infinity AUC(tr. 03`) was calculated
model-independently with the trapezoidal rule to the last measured
time point t 5 1440 min and extrapolation to infinity (cblood(1440 min)
divided by b). To compare the organ load of the different organs, the
percentage of the organ AUC(tr. 03`) was compared with the sum of
all organ AUC(tr. 03`) values. The organ load is a measure of how
much drug ever appears in one organ during the whole period be-
tween application and total elimination of the drug. The AUMC was





with the drug concentration in blood (cblood). The MRT was calculated
by dividing the AUMC with the AUC(tr. 03`).
As relative peak concentrations of NOAC in the mouse organs the
time point with highest measured drug concentration in the partic-
ular organ was considered (table 2). Further data analysis as de-
scribed by Nishikawa et al. (1993) for ara-C made it possible to
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calculate the different organ clearances and the total clearance by














with T(t1), amount of drug in the tissue at time t1 and AUC(03t1),
area under the blood concentration versus time (t03t1) curve. The
organ clearance Clorgan is given by
Clorgan 5 ClinWorgan (8)
with Worgan, organ weight in grams. To be able to compare our data
with the results of Nishikawa et al. (1993), our data were normalized
to mice of 26.5 g average body weight, and drug concentrations at 120
min were extrapolated from the blood versus time curve and the
organ concentration versus time curve.
Results
Concentration-dependent binding of NOAC and
NHAC to Ec. The binding curves of liposomal NOAC and
NHAC to Ec are shown in figure 2. The data were fitted with
a one-site binding model described by equation 1, which
results in saturation values of 63 nmol/109 Ec for NOAC and
88 nmol/109 Ec for NHAC, respectively. Saturation is
reached by use of at least 0.7 mM NOAC or 0.9 mM NHAC
under the experimental conditions. A significant difference in
the binding to Ec between NOAC and NHAC was found only
above saturation (P 5 .033, Student’s t-test, fig. 2). Linear-
ization of r versus cu according to Lineweaver-Burk (correla-
tion coefficient r 5 0.963 for NOAC and 0.992 for NHAC) or
Scatchard plots (r 5 0.869 for NOAC and 0.987 for NHAC)
resulted in 4 3 107 binding sites per Ec for NOAC and 5 3
107 for NHAC with a low binding affinity of 3 3 103 liters/mol
for both drugs. The Ec partition coefficient DEc calculated
after equation 3 was determined with the drugs (0.1 and 0.2
mM) dissolved in DMSO to avoid possible interference of the
liposomal lipids with the binding of the drugs to Ec mem-
branes. The altered drug formulation did not affect the bind-
ing characteristics of the drugs to Ec (fig. 2). For NOAC at 0.1
and 0.2 mM, a DEc of 4.2 6 0.4 resulted, whereas for NHAC
the DEc was 3.0 6 0.4 (significant difference, P 5 .0004).
According to equation 4, the fraction of drug bound to plasma
proteins fb, which was calculated with the DEc values, was
32 6 3% for NOAC and 35 6 5% for NHAC, which were not
significantly different (P 5 .236).
To exclude the possibility of the formation of drug precip-
itates in the Ec fraction, control incubations in serum with
3H-labeled NOAC dissolved in DMSO (0.28 mM incubated
with diluted serum) showed that 100 6 2% of the drug was
dissolved in the serum, and that despite the low solubility of
NOAC, no precipitates or crystals were found by microscopic
observation. Identical results were obtained with liposomal
NOAC at 1.1 mM, whereas in serum-free controls where the
drug was dissolved in DMSO, 80 to 90% of NOAC was pre-
cipitated.
Binding of NOAC to serum proteins. To further char-
acterize the binding properties of NOAC to serum proteins,
the drug was incubated (4 h, 37°C) with fresh human serum,
followed by separation of the proteins on a KBr density
gradient. To monitor the gradient after ultracentrifugation a
control run with saline/EDTA was performed and the densi-
ties of the fractions were determined. As shown in figure 3
the discontinuous gradient was smoothed after centrifuga-
tion. The separation of the lipoproteins was confirmed by
agarose gel electrophoresis of all collected serum fractions
Fig. 2. Binding curves of NOAC (E) and NHAC (F) in liposomes (0.06–
1.1 mM) to Ec determined as described under “Methods.” For a com-
parison, the binding of NOAC () and NHAC () dissolved in DMSO (0.1
and 0.2 mM) was determined under the same conditions. Drug con-
centration in Ec was determined by scintillation counting. Only the
values at 1.1 mM were significantly different (*P 5 .033; Student’s
t-test). The fit with a one-site binding model (equation 1) resulted in
saturation values of 63 nmol/109 Ec for NOAC (correlation coefficient,
r 5 0.930) and 88 nmol/109 Ec for NHAC (r 5 0.997). Each point
represents the mean 6 S.D. of three measurements. Invisible error bars
are smaller than the symbols.
Fig. 3. Distribution of NOAC (250 mM) in liposomes (F) and DMSO (E)
after incubation with human serum (4 h, 37°C) and gradient ultracen-
trifugation over a KBr gradient (d20
20 1.21, 1.064, 1.020, 1.007, 1.000;
centrifuged 22 h, 300,000 3 g, 15°C), collection of fractions (0.17 ml)
and scintillation counting for 5-3H-labeled drug activity. Control serum
(full line) was treated as described above and the proteins were mon-
itored by UV-spectroscopy (l279nm). Fractions were pooled for albumin
(fractions 4–7), HDL (fractions 11–16), LDL (fractions 19–25) and VLDL
(fractions 29–50), and the concentrations of bound drug were calcu-
lated. Additionally, the equilibrated density gradient (dashed line) given
in d20
20 after centrifugation was superimposed. Data are means of
triplicates. A comparable distribution was obtained with NHAC (not
shown). Alb., albumin.
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(data not shown). Lipoprotein-containing fractions were
pooled according to their densities and agarose gel patterns
(cf. table 1). The centrifuge tubes showed the typical density
bands where the corresponding lipoproteins were expected
(Chapman et al., 1981; Redgrave et al., 1975). Additionally, a
white band with liposomes was detected in the density range
of d20
20 1.063 to 1.019, close above the LDL band. The diam-
eters of the liposomes used ranged from 30 to 80 nm and their
density was similar to that of LDL. Therefore, it was not
possible to separate them clearly from LDL. Control centrif-
ugations containing NOAC in DMSO and with substitution of
serum by saline/EDTA resulted in a different distribution
pattern with most of the drug accumulated at d20
20 1.1034,
corresponding to the density of the solvent DMSO. This for-
mulation was used to document the binding properties of the
drug to LDL without interference of the liposomal carriers
because only drug bound to LDL appeared in fractions 19 to
25. This experiment resulted in a similar distribution pattern
as obtained with liposomal NOAC (fig. 3). With NHAC com-
parable patterns of distribution were found for all incuba-
tions (data not shown).
In table 1 the results of the serum protein distribution of
NOAC are compared with NHAC. The highest distribution of
liposomal NOAC was determined in LDL with 35.7 6 1.0%.
NHAC binding to LDL under equal conditions was 29.8 6
0.9% and significantly lower than NOAC (P 5 .0016).
There was also a significant difference between the two
formulations for the drugs bound to the HDL fraction for
NOAC (P 5 .0412) and to the LDL fraction for NHAC (P 5
.0002) caused by the nature of the preparations (cf. table 1).
However, because there was no significant difference be-
tween the binding of NOAC to LDL when applied in lipo-
somes or DMSO, we assume that the transfer of NOAC to
LDL is not impeded by the liposomes.
Further evidence that the liposomes do not retain NOAC
from the interaction with LDL is shown in figure 4. Fractions
rich in LDL had [5-3H]NOAC activity in the LDL band after
separation by agarose gel electrophoresis. This activity re-
sulted from drug bound to LDL because liposomes do not run
on agarose gels (data not shown). Similarly, the fractions rich
in HDL contained [5-3H]NOAC in the corresponding HDL
band. No radioactivity was detected in LDL-free bands (frac-
tions 6, 8, 13) and with the decreasing HDL concentrations in
the following fractions, the NOAC concentration detected in
these bands was reduced.
Pharmacokinetics of NOAC in mice. The NOAC kinetic
values in female ICR mice were determined after intrave-
nous injection of NOAC and the sacrifice of groups of three
mice at adequate time points. The blood concentration versus
time curve is biphasic, yielding a distribution half-life t1/2a of
23 min and an elimination half-life t1/2b of 7 h (fig. 5A). As
comparison, the elimination half-life t1/2b of ara-C was found
to be 21 min after i.p. administration in mice (Borsa et al.,
1969). Thus, the elimination of NOAC is 20 times slower than
that of ara-C. For the N4-hexadecyl-ara-C derivative NHAC a
similar distribution half-life t1/2a of 16 min, but a faster
elimination half-live t1/2b of 3.8 h, was determined (Horber et
al., 1995a). The total amount of NOAC found in blood
AUC(tr. 03`) was 11% dose 3 h/ml and the total clearance
Cltotal was rather low with 6 ml/h. This resulted in an appar-
ent total volume of distribution Vd(area) of 58 ml. The MRT
was 6 h. The size of the two compartments was 10 ml for the
TABLE 1





Bound Drug per Pooled Fractionsa
NOAC NHAC
Liposomes DMSO Liposomes DMSO
% %
Albuminc 4–7 11.761.8 16.662.6 18.061.7 25.064.2
(1.012–1.125)
HDL 11–16 21.060.8 25.562.5 22.361.4 23.660.2
(1.102–1.074)
LDL 19–25 35.761.0 30.463.2 29.860.9 19.761.0
(1.049–1.031)
VLDL 29–50 4.760.3 5.260.7 3.160.3 3.160.2
(1.015–1.000)
Recovery 73.161.0 77.766.9 73.261.0 71.364.0
a Average of three experiments 6 S.D.
b Density measured after ultracentrifugation (cf. fig. 3).
c Albumin and other serum proteins.
Fig. 4. Binding of NOAC to HDL (F) and LDL (E). Representative
fractions containing the lipoproteins from figure 3 were prestained with
Sudan black B and run on a 1% agarose gel (inset). The [5-3H]NOAC
concentration was determined by cutting out the corresponding bands
(graph). S, diluted serum (1:20, v/v).
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central compartment, Vc, and 33 ml for the peripheral com-
partment, Vp. Thus, shortly after intravenous bolus injection
NOAC is distributed to other compartments. Distribution
into deeper compartments occurs because Vd(area) is 3-fold
and Vp is 1.7-fold larger than the volume of total body fluids
(19 ml for mice of 25 g; Allen et al., 1992). Relative peak drug
concentrations (table 2, figs. 5 and 6) were reached shortly
after i.v. injection in blood and lung, whereas in liver and
spleen they were reached after 30 min. Correspondingly, the
peak concentration in the kidneys was found after 3 h. Most
of the drug appears in the liver with a high organ load of 69%
which can be expected for lipophilic drugs (table 2). NOAC
was eliminated from the liver with a half-life of 8 h. Thus,
after a single dose of NOAC more than 99% of the drug is
removed from the liver within 56 h (7 times t1/2b liver). Phar-
macokinetic parameters for the brain could not be calculated
because of the very low drug concentrations that were found
in this organ. Distribution into the brain is quite low with
less than 0.1% of the applied dose.
As summarized in table 3, the organ parameters of NOAC
were calculated and compared with the data for ara-C as
obtained by Nishikawa et al. (1993). Calculation of the organ
clearance Clorgan for the liver by equations 7 and 8 and
standardizing the mice to a weight of 26.5 g, as used by
Nishikawa et al. (1993), resulted in a Clliver of 2.4 ml/h. The
major elimination path of NOAC is the liver comprising 55%
of the total clearances, whereas the clearance from the kid-
neys was only 5% with a urinary clearance of 33%. The urine
clearance for NOAC was calculated by use of preliminary
data for cumulative drug excretion of mice kept in metabolic
cages for 48 h. In comparison, 80% of ara-C were cleared
through the urine (table 3).
Discussion
Binding of NOAC and NHAC to Ec. The high values of
the Ec partition coefficient DEc of 3.0 and 4.2 determined for
NHAC and NOAC reflect the lipophilicity of the drugs. The
significantly higher affinity of NOAC for Ec might be caused
by the longer alkyl chain. For comparison, Ueda and co-
workers (1983) found a similarly high accumulation of N4-
behenoyl-1-b-D-arabinofuranosylcytosine in the blood cell
membranes, which was significantly higher than binding to
plasma proteins. This drug is a comparable lipophilic N4-
acyl-ara-C derivative. The weak binding affinity of NOAC
and NHAC for Ec correlates with findings of single-chain acyl
compounds like fatty acids that are not tightly anchored
within lipid bilayers (Richieri et al., 1993; Kleinfeld and
Storch, 1993; Kamp et al., 1993). In an analytical HPLC
study, we observed significantly higher concentrations of the
drug bound to Ec, reaching a maximal Ec-to-plasma ratio of
7:1 after 6 to 8 h, after the oral application of NOAC to mice
(Rentsch et al., 1995). These results are in concordance with
the calculated protein binding value of 32% from the in vitro
incubations. By extrapolation of the calculated Ec binding
parameters to the average Ec concentration in a healthy
human (blood volume of 4.2 liters containing 2 3 1013 Ec) and
under the simplifying assumption that the Ec are the only
binding partners of the drugs, saturation would be reached
with a dose of 1.8 g NOAC or 2.4 g NHAC, respectively. With
these drug amounts a maximal Ec binding of 0.6 g NOAC and
0.8 g NHAC would be achieved. Thus, we postulate that in
Fig. 5. Blood concentration (A), liver (B) and kidney (C) distribution
versus time curves of NOAC (2.3 mg/animal) after i.v. application in
female ICR mice. Blood samples and organs were removed and pre-
pared for scintillation counting of [5-3H]NOAC as described under
“Methods.” All values were standardized to a mouse body weight of
20 g and shown as percent of injected dose. Data of the blood curve (A)
were fitted with the i.v. open two-compartment model, for which pa-
rameters were determined by the residual method. (Parameters: A,
9.2%/ml; B, 1.2%/ml; a, 0.0297/min; b, 0.0017/min; r, 0.934). Data for
the organ curves (B, C) were fitted for the elimination phase for the liver
(B, 16.9%; b, 0.0015/min; r, 0.968) and the kidneys (B, 2.0%; b,
0.00074/min; r, 0.995), respectively.
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vivo, after intravenous application of NOAC, a dynamic equi-
librium between the blood components is established, favor-
ing the initial distribution of the drug into the Ec membranes
which is followed by a redistribution into the plasma proteins
and preferentially into the lipoproteins. The binding of
NOAC to other cells is negligible, because as we showed
before with the distribution of NHAC in whole blood, only
about 2% were bound to leukocytes (Horber et al., 1995a).
Binding of NOAC and NHAC to serum proteins. The
binding characteristics of NOAC and NHAC to the lipopro-
teins and mainly to LDL suggests that LDL might function
as a natural carrier for these drugs. One reason for the
excellent therapeutic activity of NOAC against solid tumors
(Schwendener et al., 1995a), which is not observed with
ara-C, might be explained by its high affinity to LDL (fig. 3,
table 1) and its postulated carrier effect on tumor cells ex-
pressing high numbers of LDL receptors. Other investigators
(de Smidt et al., 1993; de Smidt and van Berkel, 1990) ex-
ploited this LDL carrier effect for selective drug targeting to
tumor cells with high-LDL receptor expression. Vitols et al.
(1990) observed an increased uptake with radioactively la-
beled sucrose-LDL in leukocytes of leukemic patients, which
suggested a correlation to the increased LDL receptor activ-
ity of leukemic compared with normal leukocytes. Finally,
lipophilic photosensitizer dyes were found to be associated
with lipoproteins and transported mainly by LDL to malig-
nant cells (Ginevra et al., 1990; Reddi et al., 1990; Rensen et
al., 1994; Schmidt-Erfurth et al., 1997). Therefore, LDL
might be an efficient carrier for various drugs to treat leuke-
mias and solid tumors with increased LDL turnover, e.g.,
metastatic cancer of the prostate as described by Vitols et al.
(1990). Firestone (1994) reported that there are several types
of carcinoma cells with an increased LDL uptake, especially
tumor cells that have an exceptionally high metastatic po-
tential, or that are aggressive or undifferentiated. The ratio-
nale is that large amounts of LDL are taken up by rapidly
dividing cells because an increased amount of cholesterol is
required for cell membrane assembly. However, the use of
LDL as a carrier for lipophilic drugs is limited by complicated
procedures required for its isolation from human serum and
its modification as a drug transporter molecule (Firestone,
1994; Gerke et al., 1996). These and other disadvantages,
such as the ensuing risk of infection of LDL isolated from
human blood, render the clinical use of LDL as a drug carrier
for cancer therapies rather unlikely. We found that after
incubation in serum 30 to 36% of NOAC molecules were
bound to LDL. The serum volume of 1 ml contains approxi-
mately 5.5 3 1014 LDL particles as determined and calcu-
lated by quantitative agarose gel electrophoresis (Hydragel,
TABLE 2
Pharmacokinetic parameters of NOAC after intravenous application in ICR mice
Organ Peak Concentrations Organ Loada Elimination half-time t1/2b
%b minc % h
Blood 14.1 6 0.6 4 10.8 6.9
Liver 24.4 6 2.1 30 68.8 7.9
Spleen 0.5 6 0.1 30 1.5 7.8
Kidneys 1.8 6 0.1 180 14.7 16
Lung 0.9 6 0.1 4 4.2 11
Brain 0.06 6 0.02 4 n.d.d n.d.d
a Organ AUC(tr. 03`) calculated as percent of the sum of all organ AUC(tr. 03`) values.
b Percentage of injected dose in total organ as means of triplicates 6 S.D., standardized for mice of 20 g body weight (figs. 5 and 6).
c Time of the observed relative peak concentration.
d n.d., not determined.
Fig. 6. Bar graph of spleen, lung and brain distribution of NOAC in
female ICR mice. Data calculated as percent of injected dose were
obtained after i.v. application of NOAC (2.3 mg) into the tail vein and the
sacrifice of three mice at given time points. The organs were removed
and prepared for counting [5-3H]NOAC activity as described under
“Methods.”
TABLE 3
Calculation of the organ parameters for NOAC according to
Nishikawa et al. (1993) and comparison to ara-C
Parametersa NOAC ara-Cb
Dose (mg/g)c 70 6 10 1
AUC(03120 min) (%h/ml) 11
d 3.1e
ml/h %f ml/h %
Cltotal 4,400 100 28,900 100
Clliver 2,430 55 357 1.2
Clspleen 38 1 n.a.
g
Clkidneys 214 5 n.a.
g
Clurine 1,446
h 33 23,000 80
Cllung 76 2 n.a.
g
Clbrain 5 0.1 n.a.
g
a Data calculated for mice with a 26.5-g average body weight to compare
values with Nishikawa et al. (1993) in which mice of 25–28 g were used.
b Data from Nishikawa et al. (1993).
c Dose per gram body weight.
d AUC(03120 min) calculated from blood concentration versus time curve.
e AUC(03120 min) calculated from plasma concentration versus time curve.
f Percent of the total clearance Cltotal.
g n.a., not analyzed.
h Calculated from the preliminary data of cumulative drug excretion in the urine
of mice kept in metabolic cages for 48 h and determined by use of the slope of
the excretion rate of the sampling period versus the blood concentration of
NOAC.
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Sebia, Issy-les-Moulineaux, France; data not shown). Thus,
we calculated that one LDL particle is able to bind about 100
molecules of NOAC.
The rapid transfer of NOAC from the liposome membranes
to Ec and the lipoproteins demonstrates that the liposomes
serve mainly as a pharmaceutical formulation to enable the
parenteral application of these lipophilic drugs and that their
influence on the pharmacokinetic parameters of the drugs is
marginal and probably occurs only shortly after drug injec-
tion. In another study we demonstrated that NHAC formu-
lated in long-circulating poly(ethylene glycol)-modified lipo-
somes (PEG-liposomes, Stealth liposomes) was distributed at
comparable rates to blood components as with unmodified
liposomes (Horber et al., 1995a), demonstrating that the
modified surface of the PEG-liposomes did not prevent the
transfer of the liposome membrane-associated drug to Ec and
lipoproteins. Furthermore, the antitumor activity of both
ara-C derivatives in PEG-liposomes was not significantly
improved in the L1210 mouse leukemia model compared with
drug formulations without PEG-modified liposomes (Sch-
wendener et al., 1995b), which also suggests that the antitu-
mor activity of the drugs does not depend on the liposome
composition.
Pharmacokinetics of NOAC in mice. Liposomes are
generally used to improve the blood pharmacokinetics of
encapsulated hydrophilic drugs like ara-C (Allen et al., 1992)
or doxorubicin (Vaage et al., 1994) that have short plasma
half-lives when administered in their free form. Ara-C encap-
sulated within long-circulating liposomes remains in the cir-
culation because Allen et al. (1992) determined a distribution
volume Vd of 2.2 ml (5 blood volume). Compared with free
ara-C which is distributed in the total body fluid (Vd 5 19
ml), the distribution volume of NOAC Vd(area) of 58 ml is
about three times larger, which indicates the distribution
into deeper compartments that might be caused by the high
lipophilicity of NOAC.
The further comparison of the pharmacokinetic parame-
ters of NOAC with those reported by Nishikawa et al. (1993)
for ara-C (table 3) revealed that NOAC is eliminated by urine
and through the liver, whereas ara-C is excreted mainly in
urine. Additionally, the kidney load of 15% suggests that
some of the drug or its metabolites are removed from circu-
lation by this organ. It is more likely that hydrophilic metab-
olites of NOAC are cleared by the kidneys, which is in accor-
dance with the late peak concentration of 3 h and the high
renal elimination half-life of 16 h. To confirm our findings
that NOAC and metabolites are excreted by the kidneys and
through the bile we performed the above-mentioned prelim-
inary experiment in which urine and feces were collected
during a 48-h period. As expected, we found radioactivity in
both elimination paths, namely 38% of the injected tritium
activity in the urine and 25% in the feces. Presently, we are
performing an analysis of the metabolites of NOAC from liver
homogenates, urine and fecal extracts by HPLC-mass spec-
troscopy. From the ongoing clinical phase I/II study in cancer
patients with liposomal NOAC, we determined the plasma
half-lives of the first two dosages given. At the dosages of 150
and 300 mg NOAC/m2, a t1/2a of 14 min and a t1/2b of 11 to
16 h and peak drug concentrations of 13 to 37 mM were
calculated.
In this report we demonstrated that NOAC behaves phar-
macokinetically different from ara-C and that its affinity to
LDL might prove to be a promising advantage in tumor
therapy.
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